Gilead, US Settle Billion-Dollar Patent Feud Over HIV Drugs (1)

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the bioscience giant for allegedly using joint research to develop an HIV-prevention drug regimen without compensation.

Terms of the agreement weren’t detailed in the parties’ stipulation of dismissal filed Wednesday in the US District Court for the District of Delaware, though the deal doesn’t allow either side to renew their allegations. The US on Wednesday dropped its appeal of the final judgment Judge Maryellen Noreika issued in May 2024.

“This resolution reflects the culmination of Gilead’s resounding success in these cases,” ...